autoimmune diseases of the nervous system

Summary

Summary: Disorders caused by cellular or humoral immune responses primarily directed towards nervous system autoantigens. The immune response may be directed towards specific tissue components (e.g., myelin) and may be limited to the central nervous system (e.g., MULTIPLE SCLEROSIS) or the peripheral nervous system (e.g., GUILLAIN-BARRE SYNDROME).

Top Publications

  1. ncbi New autoantibody mediated disorders of the central nervous system
    Bethan Lang
    Neurosciences Group, Department of Clinical Neurology, Weatherall Institute of Molecular Medicine, University of Oxford, UK
    Curr Opin Neurol 16:351-7. 2003
  2. ncbi Clinical and serological associations of autoantibodies to GW bodies and a novel cytoplasmic autoantigen GW182
    Theophany Eystathioy
    Department of Medicine, University of Calgary, 3330 Hospital Dr N W, Calgary, AB, T2N 4N1, Canada
    J Mol Med (Berl) 81:811-8. 2003
  3. ncbi Lambert-Eaton myasthenic syndrome
    J Newsom-Davis
    Department of Clinical Neurology, University of Oxford, Grande Bretagne
    Rev Neurol (Paris) 160:177-80. 2004
  4. ncbi Anti-MOG autoantibodies in Italian multiple sclerosis patients: specificity, sensitivity and clinical association
    Renato Mantegazza
    Immunology and Muscular Pathology Neurology IV, Istituto Nazionale Neurologico Carlo Besta, Milan, Italy
    Int Immunol 16:559-65. 2004
  5. ncbi Neurologic autoantibodies: cautious enthusiasm
    Steven Vernino
    Neurology 65:1688-9. 2005
  6. ncbi Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study
    Gillian I Rice
    Manchester Centre for Genomic Medicine, Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, Manchester Academic Health Sciences Centre MAHSC, Manchester, UK
    Lancet Neurol 12:1159-69. 2013
  7. ncbi Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain
    Daniel J Cua
    Department of Immunology, DNAX Research Inc, Palo Alto, California 94304 1104, USA
    Nature 421:744-8. 2003
  8. pmc An autoimmune disease prevented by anti-retroviral drugs
    Gabriele B Beck-Engeser
    Department of Microbiology and Immunology, University of California, San Francisco, CA 94143 0414, USA
    Retrovirology 8:91. 2011
  9. ncbi Type I interferonopathies: a novel set of inborn errors of immunity
    Yanick J Crow
    Genetic Medicine, University of Manchester, Manchester Academic Health Science Centre, Central Manchester Foundation Trust University Hospitals, United Kingdom
    Ann N Y Acad Sci 1238:91-8. 2011
  10. pmc Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies
    Josep Dalmau
    Department of Neurology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Lancet Neurol 7:1091-8. 2008

Research Grants

Detail Information

Publications202 found, 100 shown here

  1. ncbi New autoantibody mediated disorders of the central nervous system
    Bethan Lang
    Neurosciences Group, Department of Clinical Neurology, Weatherall Institute of Molecular Medicine, University of Oxford, UK
    Curr Opin Neurol 16:351-7. 2003
    ..This review summarizes the recent findings and assesses the evidence that these conditions are caused by the antibodies, using the criteria established for peripheral nervous system autoimmune diseases...
  2. ncbi Clinical and serological associations of autoantibodies to GW bodies and a novel cytoplasmic autoantigen GW182
    Theophany Eystathioy
    Department of Medicine, University of Calgary, 3330 Hospital Dr N W, Calgary, AB, T2N 4N1, Canada
    J Mol Med (Berl) 81:811-8. 2003
    ..None of the GW182 epitopes had significant sequence similarities to other known proteins. GW182 represents a new category of ribonucleoprotein autoantigens...
  3. ncbi Lambert-Eaton myasthenic syndrome
    J Newsom-Davis
    Department of Clinical Neurology, University of Oxford, Grande Bretagne
    Rev Neurol (Paris) 160:177-80. 2004
    ..In those with severe weakness, IVIg or plasmapheresis confers short-term benefits. Prednisone alone or combined with azathioprine or cyclosporin can achieve long-term control of the disorder...
  4. ncbi Anti-MOG autoantibodies in Italian multiple sclerosis patients: specificity, sensitivity and clinical association
    Renato Mantegazza
    Immunology and Muscular Pathology Neurology IV, Istituto Nazionale Neurologico Carlo Besta, Milan, Italy
    Int Immunol 16:559-65. 2004
    ..5%) of MS patients and no OND patients. Anti-MOG antibodies are not specific for MS; however, they may characterize a subset of MS patients and this may be revealed by serial assays in relation to changing disease phase...
  5. ncbi Neurologic autoantibodies: cautious enthusiasm
    Steven Vernino
    Neurology 65:1688-9. 2005
  6. ncbi Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study
    Gillian I Rice
    Manchester Centre for Genomic Medicine, Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, Manchester Academic Health Sciences Centre MAHSC, Manchester, UK
    Lancet Neurol 12:1159-69. 2013
    ..The disease is severe and effective treatments are urgently needed. We investigated the status of interferon-related biomarkers in patients with AGS with a view to future use in diagnosis and clinical trials...
  7. ncbi Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain
    Daniel J Cua
    Department of Immunology, DNAX Research Inc, Palo Alto, California 94304 1104, USA
    Nature 421:744-8. 2003
    ..In addition, we show that IL-23, unlike IL-12, acts more broadly as an end-stage effector cytokine through direct actions on macrophages...
  8. pmc An autoimmune disease prevented by anti-retroviral drugs
    Gabriele B Beck-Engeser
    Department of Microbiology and Immunology, University of California, San Francisco, CA 94143 0414, USA
    Retrovirology 8:91. 2011
    ..However, inhibition of reverse transcription by the inhibitor zidovudine (AZT) did not ameliorate the disease, weakening the link to retroelements...
  9. ncbi Type I interferonopathies: a novel set of inborn errors of immunity
    Yanick J Crow
    Genetic Medicine, University of Manchester, Manchester Academic Health Science Centre, Central Manchester Foundation Trust University Hospitals, United Kingdom
    Ann N Y Acad Sci 1238:91-8. 2011
    ....
  10. pmc Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies
    Josep Dalmau
    Department of Neurology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Lancet Neurol 7:1091-8. 2008
    ..We aimed to analyse the clinical and immunological features of patients with the disorder and examine the effects of antibodies against NMDA receptors in neuronal cultures...
  11. pmc Crystal structures of RNase H2 in complex with nucleic acid reveal the mechanism of RNA-DNA junction recognition and cleavage
    Monika P Rychlik
    Laboratory of Protein Structure, International Institute of Molecular and Cell Biology, 4 Trojdena Street, 02 109 Warsaw, Poland
    Mol Cell 40:658-70. 2010
    ..Junction recognition is important for the removal of RNA embedded in DNA and may play an important role in DNA replication and repair...
  12. pmc Cerebral arterial stenoses and stroke: novel features of Aicardi-Goutières syndrome caused by the Arg164X mutation in SAMHD1 are associated with altered cytokine expression
    Holger Thiele
    Cologne Center for Genomics, University of Cologne, 50931 Cologne, Germany
    Hum Mutat 31:E1836-50. 2010
    ..The observed vascular changes most likely reflect a vasculitis caused by dysregulated inflammatory stress response...
  13. pmc Therapies in Aicardi-Goutières syndrome
    Y J Crow
    Genetic Medicine, Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, Manchester, UK St Mary s Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
    Clin Exp Immunol 175:1-8. 2014
    ..We then discuss the pathogenesis of AGS from a molecular and cell biology perspective. Finally, we suggest possible treatment strategies in light of these emerging insights...
  14. ncbi Parkinson's disease, autoimmunity, and olfaction
    Michal Benkler
    Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Israel
    Int J Neurosci 119:2133-43. 2009
    ..We hope that understanding the nature of this disease may lay the ground for successes in the quest to halt the progressive neurodegenerative process...
  15. pmc Tourette's syndrome: a cross sectional study to examine the PANDAS hypothesis
    A J Church
    Neuroinflammation Department, Institute of Neurology, Queen Square, London, UK
    J Neurol Neurosurg Psychiatry 74:602-7. 2003
    ..Anti-basal ganglia antibodies (ABGA) are present in most cases of acute Sydenham's chorea, but rarely in controls...
  16. ncbi Immune reactivity towards insulin, its amyloid and protein S100B in blood sera of Parkinson's disease patients
    K R Wilhelm
    Department of Medical Biochemistry and Biophysics, Umea University, Umea, Sweden
    Eur J Neurol 14:327-34. 2007
    ..Immune reactions towards S100B and insulin may reflect the neurodegenerative brain damaging processes and impaired insulin homeostasis occurring in PD...
  17. ncbi Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody
    M J Thieben
    Department of Neurology, Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Neurology 62:1177-82. 2004
    ....
  18. ncbi Autoimmune channelopathies and related neurological disorders
    Angela Vincent
    Neurosciences Group, Department of Clinical Neurology, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom
    Neuron 52:123-38. 2006
    ....
  19. ncbi Expanding the phenotypic spectrum of lupus erythematosus in Aicardi-Goutières syndrome
    Georgia Ramantani
    Technische Universitat Dresden, Dresden, Germany
    Arthritis Rheum 62:1469-77. 2010
    ..In this study we further characterized the phenotypic spectrum of this disease...
  20. ncbi Sequential antibodies to potassium channels and glutamic acid decarboxylase in neuromyotonia
    C Antozzi
    Neurology Department IV, Immunology and Muscular Pathology Unit, National Neurologic Institute Carlo Besta, Milan, Italy
    Neurology 64:1290-3. 2005
    ..The range of antibodies produced in thymoma-associated neuromyotonia is richer, and the timing of antibody appearance more complex, than previously suspected...
  21. ncbi Intravenous immunoglobulin use for neurologic diseases
    Carol Lee Koski
    University of Maryland School of Medicine, Baltimore, USA
    J Infus Nurs 29:S21-8. 2006
    ..This article gives an overview of some autoimmune neurologic diseases and explores the clinical evidence supporting the use of IVIG...
  22. ncbi Use of intravenous immunoglobulin for treatment of neurologic conditions: a systematic review
    Dean Fergusson
    Clinical Epidemiology Program, Ottawa Health Research Institute, Ottawa, Ontario, Canada
    Transfusion 45:1640-57. 2005
    ....
  23. ncbi Annotation: PANDAS: a model for human autoimmune disease
    Susan E Swedo
    National Institute of Mental Health, Bethesda, Maryland 20892 1255, USA
    J Child Psychol Psychiatry 46:227-34. 2005
    ....
  24. ncbi Combined immunomodulatory therapy in autoimmune autonomic ganglionopathy
    Christopher H Gibbons
    Autonomic and Peripheral Nerve Laboratory, Department of Neurology, Beth Israel Deaconess Medical Center, 1 Deaconess Road, Boston, MA 02215, USA
    Arch Neurol 65:213-7. 2008
    ..Symptomatic and immunomodulatory therapy has provided limited clinical benefit in small uncontrolled studies...
  25. ncbi Glutamic acid decarboxylase autoimmunity in Batten disease and other disorders
    David A Pearce
    Center for Aging and Developmental Biology, Department of Biochemistry and Biophysics, Box 645, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Neurology 63:2001-5. 2004
    ....
  26. ncbi [Clinical features of neuropathies in a group of patients associated with anti-GalNAc-GD1a antibody]
    Muneto Tatsumoto
    Department of Neurology, Dokkyo University School of Medicine
    Rinsho Shinkeigaku 44:508-12. 2004
    ..Our study suggests that the anti-GalNAc-GD1a antibody testing is useful for supporting the diagnosis of GBS. In addition, fine specificity of the antibody also was clarified...
  27. ncbi Treatment of autoimmune myasthenia gravis
    Andrew C Bragdon
    Neurology 63:1138-9; author reply 1138-9. 2004
  28. ncbi Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis
    Rainer Linke
    Department of Nuclear Medicine, Klinikum Grosshadern der LMU, Munich, Germany
    Neurology 63:282-6. 2004
    ..To assess use of whole-body 18F fluoro-2-deoxy-glucose (FDG)-PET and CT for diagnosing tumor in patients with antibody-positive paraneoplastic neurologic syndromes (PNS)...
  29. ncbi Antibasal ganglia antibodies and their relevance to movement disorders
    Davide Martino
    Institute of Neurology, University College London, UK
    Curr Opin Neurol 17:425-32. 2004
    ..This review summarizes the most recent studies concerning antibasal ganglia antibodies, focusing on the associated phenotypes and the hypotheses concerning their pathogenicity...
  30. ncbi Stiff-person syndromes: motor cortex hyperexcitability correlates with anti-GAD autoimmunity
    Claudia Koerner
    Department of Neurology, Ruprecht Karls University Heidelberg, FRG
    Neurology 62:1357-62. 2004
    ....
  31. pmc Characterization of ganglionic acetylcholine receptor autoantibodies
    Steven Vernino
    Department of Neurology, UT Southwestern Medical Center, Dallas Texas 75390 9036, United States
    J Neuroimmunol 197:63-9. 2008
    ..Muscle and ganglionic AChR antibody specificities are distinct. Antibody crossreactivity between AChRs with different alpha subunits is uncommon but can occur...
  32. ncbi [Paraneoplastic peripheral neuropathies]
    J C Antoine
    Service de Neurologie, Hopital Bellevue, Saint Etienne
    Rev Neurol (Paris) 160:188-98. 2004
    ..Occasionally, the neuropathy improves with treatment of the tumor. Recent data suggest that gangliosides may be the target of the immune process in neuropathies associated with melanoma...
  33. ncbi [Immunoglobulins and physiopathology: actual indications]
    L Mouthon
    Hopital Cochin, Paris, France
    Rev Med Interne 28:11-7. 2007
    ..Mechanisms of action of IVIg are multiple and intricate. The development of new therapeutic trials in association with analyses of mechanisms of action should help to define new indications of IVIg therapy...
  34. ncbi L-DOPS therapy for refractory orthostatic hypotension in autoimmune autonomic neuropathy
    Christopher H Gibbons
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Neurology 65:1104-6. 2005
    ..L-DOPS may benefit patients with severe orthostatic intolerance and be particularly effective in patients with ganglionic NiAchR antibodies...
  35. ncbi Autoantibody-mediated disorders of the central nervous system
    Sarosh Irani
    Neurosciences Group, Department of Clinical Neurology, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, UK
    Autoimmunity 41:55-65. 2008
    ....
  36. ncbi An update on opsoclonus
    Agnes Wong
    Department of Ophthalmology and Vision Sciences, University of Toronto, Hospital for Sick Children, Toronto, Ontario, Canada
    Curr Opin Neurol 20:25-31. 2007
    ..The aim of this article is to review opsoclonus, with particular emphasis on its immunopathogenesis and pathophysiology...
  37. ncbi Diagnosis and current treatment of neurological paraneoplastic syndromes
    María José Molina-Garrido
    Department of Oncology General Universitary Hospital Elche, Alicante Spain
    Clin Transl Oncol 8:796-801. 2006
    ..The aim of this review is to analyze the variety of NPS and describe the findings concerning autoimmunity and treatments used at present...
  38. ncbi Human autoantibodies against early endosome antigen-1 enhance excitatory synaptic transmission
    S Selak
    Instituto de Neurociencias de Alicante, Consejo Superior de Investigaciones Científicas and Universidad Miguel Hernández, Aptdo 18, 03550 Sant Joan d Alacant, Spain
    Neuroscience 143:953-64. 2006
    ..These results may account for the neurological deficits observed in some patients developing EEA1 autoantibodies...
  39. ncbi Spinal cord injury triggers systemic autoimmunity: evidence for chronic B lymphocyte activation and lupus-like autoantibody synthesis
    Daniel P Ankeny
    Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University College of Medicine, Columbus, Ohio 43210, USA
    J Neurochem 99:1073-87. 2006
    ..We show a similar pathologic potential for the autoantibodies produced after SCI. Thus, mammalian SCI produces marked dysregulation of B cell function (i.e. autoimmunity) with pathological potential...
  40. ncbi Spectrum of neurological diseases associated with antibodies to minor gangliosides GM1b and GalNAc-GD1a
    M Tatsumoto
    Department of Neurology, Dokkyo Medical University School of Medicine, Kitakobayashi 880, Mibu, Shimotsuga, Tochigi 321 0293, Japan
    J Neuroimmunol 177:201-8. 2006
    ..A method to prepare GM1b was developed...
  41. ncbi Relapses after treatment with rituximab in a patient with multiple sclerosis and anti myelin-associated glycoprotein polyneuropathy
    Luana Benedetti
    Department of Neurosciences, Ophthalmology, and Genetics, University of Genova, Via De Toni 5, 16132 Genova, Italy
    Arch Neurol 64:1531-3. 2007
    ..To describe the unique case of a patient with multiple sclerosis (MS) and anti-myelin-associated glycoprotein (MAG) polyneuropathy who developed MS relapses after treatment with rituximab...
  42. ncbi Transglutaminase-independent binding of gliadin to intestinal brush border membrane and GM1 ganglioside
    Armin Alaedini
    Department of Neurology and Neuroscience, 1300 York Ave, Weill Medical College of Cornell University, New York, NY 10021, USA
    J Neuroimmunol 177:167-72. 2006
    ..Furthermore, binding of gliadin to GM1 on the intestinal epithelium might have a role in the anti-gliadin immune response and contribute to the intestinal inflammatory reaction in celiac disease...
  43. ncbi Autoantibodies associated with psychiatric disorders
    Paola Margutti
    Dipartimento di Malattie Infettive, Parassitarie e Immunomediate, Istituto Superiore di Sanita, Rome, Italy
    Curr Neurovasc Res 3:149-57. 2006
    ....
  44. ncbi Serum autoantibodies do not differentiate PANDAS and Tourette syndrome from controls
    R C Dale
    Neurology 66:1612; author reply 1612. 2006
  45. ncbi [The use of intravenous immunglobulin in the treatment of autoimmune neuromuscular diseases]
    Maria Judit Molnar
    Orszagos Pszichiatriai es Neurologiai Intezet, Budapest
    Ideggyogy Sz 59:98-106. 2006
    ..For the analysis of pharmacoeconomical aspects and the mechanism(s) of response differences in the same disease categories, further studies are necessary...
  46. ncbi Tic disorders and obsessive-compulsive disorder: is autoimmunity involved?
    Pieter J Hoekstra
    Child and Adolescent Psychiatry Centre, Groningen, The Netherlands
    Int Rev Psychiatry 17:497-502. 2005
    ..Future longitudinal studies should be aimed at assessing the precise relationship between symptom exacerbations, infections, and immune parameters, possibly along with gene expression profiles...
  47. ncbi Gangliosides as targets for autoimmune injury to the nervous system
    Hugh J Willison
    Division of Clinical Neurosciences, University of Glasgow, Scotland
    J Neurochem 103:143-9. 2007
    ....
  48. ncbi Autoantibody-mediated bowel and bladder dysfunction in a patient with chronic, nondiabetic neuropathy
    Michael W Jackson
    Autoimmunity Research Laboratory, Department of Immunology, Allergy and Arthritis, Flinders Medical Centre and Flinders University, Adelaide, SA, Australia
    Muscle Nerve 37:537-43. 2008
    ..Although the target antigen is unknown, it is likely to be a cell-surface receptor or ion channel. This case highlights the usefulness of passive transfer studies in detecting functional antibodies in patients with autonomic neuropathy...
  49. ncbi Autoreactive antibodies against neurons and basal lamina found in serum following experimental brain contusion in rats
    S Rudehill
    Department of Clinical Neuroscience, Section of Neurosurgery, Karolinska Institute, Stockholm, Sweden
    Acta Neurochir (Wien) 148:199-205; discussion 205. 2006
    ..CNS injuries may cause anti-brain reactivity. This study was undertaken to analyze the pattern of delayed post-traumatic anti-brain immunity in experimental brain contusion...
  50. ncbi Alpha7-acetylcholine receptor antibodies in two patients with Rasmussen encephalitis
    R Watson
    Neurosciences Group, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK
    Neurology 65:1802-4. 2005
    ..Thus, the alpha7 nAChR is a potential target for pathogenic antibodies in patients with RE...
  51. ncbi Activation of humoral immunity and eosinophils in neuromyelitis optica
    Jorge Correale
    Raul Carrea Institute for Neurological Research, FLENI, Montañeses 2325 1428, Buenos Aires, Argentina
    Neurology 63:2363-70. 2004
    ..To study immunologic alterations in patients with neuromyelitis optica (NMO)...
  52. pmc Autonomic "myasthenia": the case for an autoimmune pathogenesis
    Daniel B Drachman
    Department of Neurology and Neuroscience, Johns Hopkins School of Medicine, Baltimore, Maryland 21287, USA
    J Clin Invest 111:797-9. 2003
  53. ncbi A family with Campylobacter enteritis: anti-GD1a antibody with/without Guillain-Barré syndrome
    M Hirano
    Department of Neurology, Nara Medical University, Kashihara, Japan
    Neurology 60:1719-20. 2003
  54. ncbi Alpha-fodrin autoantibodies in the differential diagnosis of MS and Sjögren syndrome
    J de Seze
    Department of Neurology, University of Lille, France
    Neurology 61:268-9. 2003
  55. ncbi GalNAc-GD1a in human peripheral nerve: target sites of anti-ganglioside antibody
    K Kaida
    Third Department of Internal Medicine, National Defense Medical College, Saitama Ken, Japan
    Neurology 61:465-70. 2003
    ..Elucidation of the localization of GalNAc-GD1a in human peripheral nerve tissue may lead to understanding of the pathogenetic role of anti-GalNAc-GD1a antibody in GBS...
  56. ncbi Cerebellar ataxia as a possible organ-specific autoimmune disease
    Marios Hadjivassiliou
    Department of Neurology, The Royal Hallamshire Hospital, Glossop Road, Sheffield, UK
    Mov Disord 23:1370-7. 2008
    ....
  57. ncbi Neuropathology and binding studies in anti-amphiphysin-associated stiff-person syndrome
    C Wessig
    Department of Neurology, University of Wurzburg, Germany
    Neurology 61:195-8. 2003
    ..Later, the encephalopathy progressed rapidly and the patient died. Binding studies and the detection of autoantibodies in the patient's CNS as well as the treatment response suggest a pathogenic role of the anti-amphiphysin antibodies...
  58. ncbi Association of chronic progressive neurological disease and ubiquitous viral agents: lessons from human herpesvirus 6 and multiple sclerosis
    A Fogdell-Hahn
    Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke NIH, 9000 Rockville Pike, Building 10, Room 5B 16, Bethesda, MD 20892, USA
    Mol Psychiatry 7:S29-31. 2002
  59. pmc Immunization with neuronal nicotinic acetylcholine receptor induces neurological autoimmune disease
    Vanda A Lennon
    Department of Immunology, Mayo Graduate and Medical Schools and Mayo Clinic, Rochester, Minnesota 55905, USA
    J Clin Invest 111:907-13. 2003
    ....
  60. ncbi [About "Multiple sclerosis and autoimmune diseases" ]
    A Spadaro
    Reumatismo 54:68. 2002
  61. pmc Myelin protein P0-specific IgM producing monoclonal B cell lines were established from polyneuropathy patients with monoclonal gammopathy of undetermined significance (MGUS)
    M Kvarnstrom
    Department of Health and Environment, Linkoping University, Sweden
    Clin Exp Immunol 127:255-62. 2002
    ..The cell lines may provide useful tools in studies of monoclonal gammopathies, leukaemia, and autoimmune diseases, including aspects of antigen-presentation by these cells followed by T cell activation...
  62. pmc Anti-GQ1b IgG antibody syndrome: clinical and immunological range
    S Panda
    J Neurol Neurosurg Psychiatry 72:418-9. 2002
  63. ncbi The spectrum of autoimmune autonomic neuropathies
    Caroline M Klein
    Department of Neurology, Medical University of South Carolina, Charleston, SC, USA
    Ann Neurol 53:752-8. 2003
    ....
  64. ncbi Autoantigens in human neuroblastoma cells
    J Srinivasan
    Department of Neurology, Columbia University, College of Physicians and Surgeons, New York City, NY 10032
    J Neuroimmunol 26:43-50. 1990
    Neuroblastoma cells are frequently used as targets in studies of autoimmune diseases of the nervous system. We examined the human neuroblastoma cell line, LAN-5, for the presence of autoantigens that react with naturally occurring ..
  65. ncbi Glucocorticosteroids modulate antigen-induced T cell apoptosis in experimental autoimmune neuritis and cause T cell proliferation in situ
    A Weishaupt
    Department of Neurology, Clinical Research Group for Multiple Sclerosis and Neuroimmunology, Julius Maximilians Universitat, Wurzburg, Germany
    Acta Neuropathol 102:75-82. 2001
    ..In this scenario even local T cell proliferation in the inflamed nervous system occurs. These results support the paradigm of antigen presentation in the nervous system...
  66. ncbi Role of TNF-alpha in high-dose antigen therapy in experimental autoimmune neuritis: inhibition of TNF-alpha by neutralizing antibodies reduces T-cell apoptosis and prevents liver necrosis
    A Weishaupt
    Department of Neurology, Julius Maximilians Universitat, Wurzburg, Germany
    J Neuropathol Exp Neurol 59:368-76. 2000
    ..These results indicate that secretion of TNF-alpha during antigen therapy has the dual potential to mediate beneficial apoptosis of inflammatory T-cells in the inflammatory lesion and to induce liver damage as a severe side effect...
  67. pmc Myelin basic protein-primed T cells induce nitric oxide synthase in microglial cells. Implications for multiple sclerosis
    Subhajit Dasgupta
    Department of Oral Biology, University of Nebraska Medical Center, Lincoln, Nebraska 68583, USA
    J Biol Chem 277:39327-33. 2002
    ..This study illustrates a novel role of neuroantigen-primed T cells in inducing contact-mediated expression of iNOS in microglial cells that may participate in the pathogenesis of MS...
  68. pmc Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy
    Meleeneh Kazarian
    Department of Surgery, Norris Cancer Center, Keck School of Medicine, University of Southern California, 1441 Eastlake Ave, NOR 6420, Los Angeles, CA 90089 9176, USA
    Mol Cancer 10:33. 2011
    ..We also discuss potential clinical applications for these autoantibodies, such as SCLC diagnosis, early detection, and therapy...
  69. ncbi Termination of inflammation in the nervous system
    R Gold
    Department of Neurology, St Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, 44791 Bochum, Germany
    Rev Neurol (Paris) 163:672-6. 2007
    ..We also discuss regulatory, proapoptotic mechanisms such as the Fas/FasL system and counterregulatory mechanisms that have been utilized to limit tissue damage...
  70. pmc Chemokines as pain mediators and modulators
    Fletcher A White
    Department of Cell Biology, Loyola University Chicago, Maywood, Illinois 60153, USA
    Curr Opin Anaesthesiol 21:580-5. 2008
    ....
  71. ncbi Intravenous immunoglobulin in MS: promise or failure?
    Franz Fazekas
    Department of Neurology, Medical University Graz, Auenbruggerplatz 22, A 8036 Graz, Austria
    J Neurol Sci 259:61-6. 2007
    ..Consequently, IVIG treatment may be considered as second line option for these indications although there is still uncertainty regarding the actual mechanism(s) of action and optimal dosage of this treatment...
  72. ncbi Immunoneutralization of chemokines for the prevention and treatment of central nervous system autoimmune disease
    William J Karpus
    Department of Pathology, The Feinberg School of Medicine, Northwestern University, 303 E Chicago Avenue, W127, Chicago, IL 60611, USA
    Methods 29:362-8. 2003
    ....
  73. ncbi Inflammatory cytokines in the nervous system: multifunctional mediators in autoimmunity and cerebral ischemia
    G Stoll
    Department of Neurology, Julius Maximilians Universitat, Wurzburg, Germany
    Rev Neurol (Paris) 158:887-91. 2002
    ....
  74. ncbi APC derived from donor splenocytes support retinal autoimmune disease in allogeneic recipients
    Dale S Gregerson
    Department of Opthamology, University of Minnesota, Lions Research Building, Rm 314, 2001 6th Street, S E, Minneapolis, MN 55455, USA
    J Leukoc Biol 76:383-7. 2004
    ..microglia are now widely regarded to play a critical role in the expression of experimental autoimmune diseases of the nervous system. Similar results might be expected in the experimental autoimmune uveoretinitis model, as retina ..
  75. ncbi Quantification and functional characterization of antibodies to native aquaporin 4 in neuromyelitis optica
    Sudhakar Reddy Kalluri
    Department of Neurology, Klinikum rechts der Isar, Technische Universitat Munchen, Munchen, Germany
    Arch Neurol 67:1201-8. 2010
    Antibodies targeting membrane proteins play an important role in various autoimmune diseases of the nervous system. So far, assays allowing proper analysis of such autoantibodies are largely missing...
  76. ncbi The natural history of B cells
    Nancy L Monson
    University of Texas Southwestern Medical School, Dallas, Texas, USA
    Curr Opin Neurol 21:S3-8. 2008
    ..Further research is needed to elucidate the pathology of B cells and their role in central nervous system autoimmune diseases, including multiple sclerosis...
  77. ncbi Antibodies to neuron-specific antigens in children with autism: possible cross-reaction with encephalitogenic proteins from milk, Chlamydia pneumoniae and Streptococcus group A
    A Vojdani
    Section of Neuroimmunology, Immunosciences Laboratory, Inc, 8693 Wilshire Boulevard, Suite 200, Beverly Hills, CA 90211, USA
    J Neuroimmunol 129:168-77. 2002
    ..These results suggest a mechanism by which bacterial infections and milk antigens may modulate autoimmune responses in autism...
  78. ncbi Antibodies against GluR3 peptides are not specific for Rasmussen's encephalitis but are also present in epilepsy patients with severe, early onset disease and intractable seizures
    Renato Mantegazza
    Immunology and Muscular Pathology Unit, Istituto Nazionale Neurologico Carlo Besta, Via Celoria 11, Milan, Italy
    J Neuroimmunol 131:179-85. 2002
    ..Antibodies against GluR3B peptide were significantly associated with frequent seizures compared to occasional or drug-controlled seizures...
  79. ncbi CSF and serum immune parameters in Sydenham's chorea: evidence of an autoimmune syndrome?
    Andrew J Church
    Neuroimmunology Unit, Neuroinflammation Department, Institute of Neurology, Room 917, Queen Square, London WC1N 3BG, UK
    J Neuroimmunol 136:149-53. 2003
    ..OCB were found in 46% of acute SC, ABGA were in 93% of acute SC and 50% of persistent SC was of IgG(1) and IgG(3) subclass. These findings support an autoantibody pathogenesis...
  80. ncbi Channels, currents and mechanisms of accommodative processes in simulated cases of systematic demyelinating neuropathies
    Diana I Stephanova
    Institute of Biophysics, Bulgarian Academy of Sciences, Sofia, Bulgaria
    Brain Res 1171:138-51. 2007
    ....
  81. ncbi Prevalence and characteristics of immunomediated neuropathies in a group of patients with autoimmune diseases
    Luisa Servioli
    Autoimmune Diseases Unit, Department of Internal Medicine, Medical Clinic 1, Montevideo, Uruguay
    J Clin Neuromuscul Dis 9:285-90. 2007
    ..To determine the prevalence and the clinical-neurophysiological characteristics of immunomediated peripheral neuropathies (PN) in a group of patients with systemic autoimmune diseases...
  82. ncbi Failure of memory (CD44 high) CD4 T cells to recognize their target antigen in retina
    D S Gregerson
    Department of Ophthalmology, University of Minnesota, Minneapolis, MN 55455, USA
    J Neuroimmunol 120:34-41. 2001
    ..We conclude that sequestration provides a substantial barrier to recognition of Ag in quiet retina, and that insufficient Ag leaves the retina for detectable immune recognition outside of the retina...
  83. ncbi [Anti-basal ganglia antibody]
    Masaharu Hayashi
    Department of Brain Development and Neural Regeneration, Tokyo Metropolitan Institute of Medical Science, Japan
    Brain Nerve 65:377-84. 2013
    ..The sera from patients showing involuntary movements had immunoreactivity for basal ganglia neurons. Further epitopes for ABGA will be investigated in basal ganglia disorders other than SC, TS, OCD, and PANDAS...
  84. ncbi [Dysimmune peripheral neuropathies: evaluation of treatment]
    G Nicolas
    Departement de Neurologie, CHU Angers, 4, rue Larrey, 49933 Angers Cedex 9, France
    Rev Neurol (Paris) 163:3S77-84. 2007
    ..The use of composite scales, mixing the evaluation of deficits, electrophysiological data and functional issues, is a promising solution, but the relative value of these parameters still remains to be defined...
  85. ncbi [Susceptible and resistant factors in neuro-immune disease]
    Shinya Sato
    Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University
    Nihon Rinsho 71:783-8. 2013
    ..This review aims to discuss susceptible and resistant factors that have attracted the most attention in the recent years, especially focusing on multiple sclerosis, which is one of the most common NIDs...
  86. ncbi Polyclonal immunoglobulin G for autoimmune demyelinating nervous system disorders
    Mathias Buttmann
    Department of Neurology, University of Wurzburg, Josef Schneider Str 11, D 97080 Wurzburg, Germany
    Trends Pharmacol Sci 34:445-57. 2013
    ....
  87. ncbi Striking intrafamilial phenotypic variability in Aicardi-Goutières syndrome associated with the recurrent Asian founder mutation in RNASEH2C
    Julie Vogt
    Centre for Rare Diseases and Personalised Medicine, Department of Medical and Molecular Genetics, School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, UK
    Am J Med Genet A 161:338-42. 2013
    ..In addition, marked phenotypic variation raises the possibility that more mildly affected patients are not currently identified...
  88. ncbi Anti-ganglioside complex IgM antibodies in multifocal motor neuropathy and chronic immune-mediated neuropathies
    Eduardo Nobile-Orazio
    Department of Translational Medicine, Milan University, Milan, Italy 2nd Neurology, IRCCS Humanitas Clinical Institute, Rozzano, Milan, Italy
    J Neuroimmunol 219:119-22. 2010
    ..IgM binding to gangliosides was however often modified in GSCs suggesting that these reactivities may be affected by contiguous gangliosides possibly influencing their pathogenicity...
  89. ncbi Autism: an emerging 'neuroimmune disorder' in search of therapy
    Theoharis C Theoharides
    Molecular Immunopharmacology and Drug Discovery Laboratory, Tufts University School of Medicine, Tufts Medical Center, Department of Pharmacology, Boston, MA 02111, USA
    Expert Opin Pharmacother 10:2127-43. 2009
    ..There is no reliable screening test, and no definite pathogenesis or curative therapy. Consequently, there is a major gap hampering development of effective treatments...
  90. pmc Type17 T-cells in central nervous system autoimmunity and tumors
    Hideho Okada
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    J Clin Immunol 32:802-8. 2012
    ..The insight gained from these findings may lead to the development of novel therapeutic and prophylactic strategies for CNS autoimmunity and tumors...
  91. ncbi The CD4-Th1 model for multiple sclerosis: a critical [correction of crucial] re-appraisal
    Hans Lassmann
    Division of Neuroimmunology, Brain Research Institute, University of Vienna, Spitalgasse 4, A 1090 Vienna, Austria
    Trends Immunol 25:132-7. 2004
  92. ncbi Chronic ataxic neuropathy with cold agglutinins: atypical phenotype and response to anti-CD20 antibodies
    K Siddiqui
    Department of Neurology, Beaumont Hospital, Dublin, Republic of Ireland
    Neurology 61:1307-8. 2003
  93. ncbi Treatment of limbic encephalitis with anti-glioma-inactivated 1 (LGI1) antibodies
    E Krastinova
    Department of Internal Medicine, CHU de Bicetre, 78, rue du General Leclerc, 94275 Kremlin Bicêtre, France
    J Clin Neurosci 19:1580-2. 2012
    ..Anti-glioma-inactivated 1 (LGI1) antibodies have been recently identified as associated with limbic encephalitis, as was the case in our patient...
  94. ncbi [Neurologic paraneoplastic syndrome with anti-CV2/CRMP5 antibodies revealing a small cell lung cancer. Effectiveness of the lung cancer treatment]
    L Rosencher
    Service de Pneumologie, Hopital Tenon, 4, rue de la Chine, 75970 Paris, France
    Rev Neurol (Paris) 168:371-4. 2012
    ..Various clinical manifestations can occur, cerebellar ataxia, polyneuropathy, optic neuritis with NORB or uveitis. Small cell lung carcinoma is generally responsible...
  95. ncbi [Treatment with intravenous immunoglobulin in neurological diseases. A descriptive study of effects seen from the patient's and health services' perspectives]
    Anne Wintzell
    Apoteket AB Sjukhusapoteket, Universitetssjukhuset i Lund
    Lakartidningen 105:1571-5. 2008
  96. ncbi Thromboembolic complications of intravenous immunoglobulin treatment
    S Vucic
    Massachusetts General Hospital, Boston, Mass 021114, USA
    Eur Neurol 52:141-4. 2004
    ..Therefore, the clinicians should be vigilant about the possibility of thromboembolic complications with each IVIg infusion and be especially judicious with the use of IVIg in patients with underlying risk factors...
  97. ncbi [PANDAS--Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection: is it a specific clinical disorder?]
    Harvey S Singer
    Rev Bras Psiquiatr 26:220-1. 2004
  98. ncbi Autoimmunity in autism
    Amanda M Enstrom
    University of California at Davis, Department of Medical Microbiology and Immunology UC Davis MIND Institute, 2805 50th Street, Sacramento, CA 95817, USA
    Curr Opin Investig Drugs 10:463-73. 2009
    ..A better understanding of the involvement of the immune response in early brain development, with respect to autism, may have important therapeutic implications...
  99. ncbi Recognizable phenotypes associated with intracranial calcification
    John H Livingston
    Department of Paediatric Neurology, Leeds General Infirmary, Leeds, UK
    Dev Med Child Neurol 55:46-57. 2013
    ....
  100. ncbi [Anti-NMDA receptor encephalitis: two paediatric cases]
    M Cristina González-Toro
    Hospital General Universitario de Alicante, 03010 San Vicente del Raspeig, Espana
    Rev Neurol 57:504-8. 2013
    ..We report two cases from our own experience with similar clinical pictures...
  101. ncbi Antibodies to the N-methyl-D-aspartate receptor and other synaptic proteins in psychosis
    Julia Deakin
    Department of Psychiatry, University of Cambridge, Cambridge
    Biol Psychiatry 75:284-91. 2014
    ..We discuss the evidence for this from the field of paraneoplastic neurologic syndromes and the discovery of novel cell surface antigen central nervous system autoimmune syndromes. ..

Research Grants44

  1. Pharmacogenetics in Tourette Syndrom
    Harvey Singer; Fiscal Year: 2004
    ..The identification of genetic polymorphisms that are associated with clinical disease or treatment success, has obvious benefits. ..
  2. Mechanisms of Jedi-mediated engulfment of apoptotic cells
    CHELSEA SUZANNE SULLIVAN; Fiscal Year: 2013
    ..2007). Determining the mechanisms of apoptotic neuron clearance will benefit our understanding of mammalian nervous system development and possibly provide vital insights into the etiology of autoimmune disorders of the nervous system. ..
  3. Experimental Dysautonomia: Pathogenesis and Treatment
    Steven Vernino; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  4. INDUCTION OF APOPTOSIS BY HIV-1 VPR
    Vicente Planelles; Fiscal Year: 2010
    ..We also hypothesize that ATR activation by Vpr, when allowed, will result in enhanced rate of viral replication. ..
  5. Naltrexone for Bipolar Disorder and Alcohol Dependence
    E Sherwood Brown; Fiscal Year: 2006
    ..Alcohol use is the primary outcome, and alcohol craving is the secondary outcome. Manic and depressive symptom severity and the relationship between changes in alcohol use and changes in mood will be expIored. ..
  6. Transport of TNFalpha across the BBB
    Weihong Pan; Fiscal Year: 2008
    ..These transporters could be novel drug targets and therefore provide promising therapeutic potential. [unreadable] [unreadable]..
  7. Transport of neurotrophic cytokines after spinal cord injury
    Weihong Pan; Fiscal Year: 2007
    ..Understanding the mechanisms of cytokine transport at this regulatory interface would help in the design of new approaches to treat SCI. ..
  8. Characterization of Dementia with Lewy Bodies: A Collaborative Study
    Thomas Montine; Fiscal Year: 2007
    ..This resource will be made available for future investigations of DLB. ..
  9. Lipid Oxidation Products in Alzheimer's Disease
    Thomas Montine; Fiscal Year: 2007
    ..abstract_text> ..
  10. 11th International Congress on Neuronal Ceroid Lipofuscinosis
    David Pearce; Fiscal Year: 2007
    ..The Congress will aid interactions of researchers that will hopefully expedite a greater understanding for these diseases. [unreadable] [unreadable] [unreadable]..
  11. Mast cells, antidepressants and chronic fatigue syndrome
    Theoharis Theoharides; Fiscal Year: 2007
    ..Future studies will build on these findings to develop in vitro and in vivo models of CFS and lead to clinical trials with select antidepressants or other molecules that inhibit brain mast cells. [unreadable] [unreadable] [unreadable]..
  12. Tumor Suppressors in Lymphocytes
    Matthias Wabl; Fiscal Year: 2008
    ..Subsequently, a subset of them will be further characterized and the nature of their cooperation with other oncogenes (co-mutations) will be determined. ..
  13. Immune reactivity to synapsin in the neuropathy and ataxia of celiac disease
    Armin Alaedini; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  14. Potentiation of photic circadian clock phase shifts
    Mary Harrington; Fiscal Year: 2007
    ..The progress of cancer is slower in patients with enhanced circadian rhythmicity, a benefit that might accrue from better circadian entrainment [unreadable] [unreadable]..
  15. Proteomic Discovery in Parkinson-Dementia Complex of Guam
    Thomas Montine; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  16. Treatment of Hypochondriasis with CBT &/or SSRI
    Brian A Fallon; Fiscal Year: 2010
    ..Most recently, the 2004 National Advisory Mental Health Council's Workgroup on Clinical Trials stated: "the portfolio must include more research in this area"...
  17. ORAL TOLERANCE IN PLP INDUCED EAE--MOLECULAR MECHANISMS
    William Karpus; Fiscal Year: 2003
    ..These studies should lead to a better understanding of the immunoregulatory mechanisms of oral tolerance which could potentially be used to control pathologic T cell-mediated immune responses. ..
  18. PET AND MRI IMAGING OF PERSISTENT LYME ENCEPHALOPATHY
    Brian Fallon; Fiscal Year: 2003
    ..This study will enhance our understanding of the pathophysiology and treatment of patients suffering with the disabling effects of persistent Lyme encephalopathy. ..
  19. DIABETIC AUTONOMIC NEUROPATHY
    Phillip Low; Fiscal Year: 2001
    ..abstract_text> ..
  20. CATECHOL THIOETHERS IN PARKINSON'S DISEASE
    Thomas Montine; Fiscal Year: 2004
    ....
  21. Activation of a DNA damage pathway by HIV-1 vpr
    Vicente Planelles; Fiscal Year: 2003
    ..The goal of this proposal is to elucidate the specific steps of the DNA-response pathway that are activated by Vpr, and to compare such steps with the physiological activator, DNA damage. ..
  22. Peripheral Nerve Ischemia
    Phillip Low; Fiscal Year: 2004
    ..We will then define the therapeutic windows and evaluate the mechanisms of production of hypothermic and antioxidant neuroprotection (Specific aim number 2) from reperfusion injury. ..
  23. HIPPOCAMPAL FUNCTION DURING CORTICOSTEROID THERAPY
    E Sherwood Brown; Fiscal Year: 2004
    ..Through this award, the Pl will extend his previous research experience by adding new skills and knowledge which will be used for investigations at the interface of neuroscience and clinical research. ..
  24. THE ROLE OF CHEMOKINES IN AUTOIMMUNE ENCEPHALOMYELITIS
    William Karpus; Fiscal Year: 2009
    ..These studies will help to understand the immunopathogenesis of MS and provide a basis for the development of novel chemokine and chemokine receptor therapies for treatment of ongoing disease. ..
  25. Vaccination With Peptide-loaded alphaDC1s For Malignant Gliomas
    Hideho Okada; Fiscal Year: 2008
    ..Information from this pilot study will establish a basis to design subsequent trials with patient populations in which more significant clinical benefit might be realized. ..
  26. HIV infection and drugs of abuse in neuroglial function
    Carlos Pardo Villamizar; Fiscal Year: 2007
    ..The results of these studies will facilitate a better understanding of the mechanisms of injury in HIV infection and drug abuse and will provide insight into the design of more effective therapeutics. ..
  27. LIPID PEROXIDATION AND APOE IN ALZHEIMERS DISEASE
    Thomas Montine; Fiscal Year: 2003
    ..This new information will aid in laying the foundation for designing rational therapeutic approaches to ameliorate brain oxidative damage in Alzheimer's disease. ..
  28. Regulation of Oligodendrocyte Survival
    Horea Rus; Fiscal Year: 2006
    ..Our proposed studies will provide an unique model system to elucidate the biology of sublethally injured OLG and may lead to the identification of regulatory factors that can enhance OLG survival and remyelination. ..
  29. Hypocretin System Immune Diathesis in Human Narcolepsy
    John Black; Fiscal Year: 2004
    ..Long term objectives: This translational, multidisciplinary research will demonstrate fundamental insights into the cause of narcolepsy and will open avenues for new interventions and preventative measures for this debilitating disease. ..
  30. IN VIVO TREATMENT OF EAE WITH ANTI I-A ANTIBODIES
    Lawrence Steinman; Fiscal Year: 2001
    ..Aim 5 is to assess the possibility of using DNA vaccination against TCR Vb for treatment of EAE. It is hoped that these studies will provide the basis for future clinical trials in MS patients. ..
  31. OspA and autoimmunity in chronic Lyme disease
    Armin Alaedini; Fiscal Year: 2007
    ..Identification of specific immune reactivity to an autoantigen might also be useful as a diagnostic marker and for monitoring of disease activity in affected patients. [unreadable] [unreadable] [unreadable]..
  32. EAMG: MIR structure and specific immunosuppressive therapy
    Jon Lindstrom; Fiscal Year: 2009
    ..Our long term goal is to test an optimized therapy on canine MG as a model for human studies. ..
  33. HEAT SHOCK PROTEINS AND THEIR ANTIBODIES IN GLAUCOMA
    Martin Wax; Fiscal Year: 2002
    ..Finally, they will utilize a yeast "two-hydrid" system to identify genes encoding potentially novel proteins that bind and interact with retinal heat shock proteins. ..
  34. RETINAL CELL MODEL FOR BATTEN DISEASE
    David Pearce; Fiscal Year: 2002
    ....
  35. Serum Proteomics for Biomarker Discovery in Batten Disease
    David Pearce; Fiscal Year: 2008
    ..Completion of the proposed studies would likely prove valuable in identification of markers of more complex neurodegenerative diseases [unreadable] [unreadable] [unreadable] [unreadable]..
  36. CORTICOTROPIN RELEASING HORMONE INDUCED DURA MAST CELL A
    Theoharis Theoharides; Fiscal Year: 2001
    ..They may also help explain some key events in the pathophysiology of migraines, the clinical symptoms of which are often precipitated by stress. ..
  37. Restraint stress-induced neurogenic bladder inflammation
    Theoharis Theoharides; Fiscal Year: 2006
    ..Our findings may be relevant to the pathophysiology of IC and may suggest new therapeutic approaches. ..
  38. Spectrum of Autoimmune Gastrointestinal Dysmotility
    Vanda Lennon; Fiscal Year: 2009
    ..l.dysmotilities, and justify early consideration of immunomodulatory therapies. The proposed research also has high clinical relevance to cancer immunity. ..
  39. Treating Asthma Patients with Major Depressive Disorder
    E Sherwood Brown; Fiscal Year: 2004
    ....
  40. PEPTIDE MEDIATED IMMUNOTHERAPY FOR AUTOIMMUNE DISEASE
    Lawrence Steinman; Fiscal Year: 2003
    ..This work with APL may be applicable not only to MS, but to other autoimmune diseases including juvenile diabetes, rheumatoid arthritis, and inflammatory bowel disease. ..
  41. CORNEAL ENDOTHELIAL CELL IMMUNOREGULATORY FACTORS
    DALE GREGERSON; Fiscal Year: 2003
    ..identify the activity(s) to learn if it is a known factor(s); and 3. if the activity has not already been described, continue characterization of the factor(s) and mechanism of action. ..
  42. Large Scale Images of Gene Transcription in MS and EAE
    Lawrence Steinman; Fiscal Year: 2004
    ..The discovery of the role of osteopontin, first identified in large scale profiles, exemplifies how this approach may help us to understand MS and to develop new therapies. ..